ArticleSurgical endoscopy2026
Secular trends of endoscopic sleeve gastroplasty: analysis of the MBSAQIP database.
Article in Surgical endoscopy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsEndoscopic sleeve gastroplasty (ESG) is a minimally invasive endoluminal procedure for the management of obesity and has become increasingly popular in patients who are poor surgical candidates or who choose against surgical intervention. This study aims to evaluate secular trends of ESG in a large bariatric procedure-specific clinical database.
methodsWe analyzed patients who underwent ESG from 2020 to 2023 from the Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program (MBSAQIP). Annual incidence, patient characteristics and trends in 30-day serious adverse events following ESG were collected.
resultsA total of 2371 patients (mean age 45y, 85.8% F, mean BMI 40 kg/m
conclusionThe number of ESGs being performed has significantly increased over the past few years. Despite expanding ESG to a higher-risk patient population, the incidence of serious adverse events following ESG has remained extremely low with no significant increase over the study period. As endoscopic techniques continue to evolve, ESG acts as a model for the future of endoluminal therapies in high-risk patient populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.